Publications

5891 Results

Assessment of Outcomes of Allogeneic Stem Cell Transplantation by Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Authors
M Liedtke;Z Sun;M Litzow;R Mattison;E Paietta;K Roberts;Y Zhang;J Racevckis;H Lazarus;J Rowe;D Arber;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D DeAngelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;M Wieduwilt
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1910

Reexamining NCTN Clinical Trials for Sex Differences in Outcomes and Toxicities in Patients with Neuroendocrine Neoplasms

Authors
W Tan;L Cramer;N Vijayvergia;M Lustberg;M Kulke;J Yao;P Kunz
Journal / Conference
NANETS Symposium (North American Neuroendocrine Tumor Society (Nov 21-23, 2024, Chicago, IL), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80701, CTSU/E2211, S0518

Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer

Authors
P Singh;L Ballas;G Sonpavde;R Chen;R Bangs;B Baumann;H Nagar;H Nagar;S Delacroix;S Lerner;J Efstathiou
Journal / Conference
Bladder Cancer Oct 23;10(3):199-213
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID39493817
PMC
PMC11530036
Study Number(s)
S1806

A Randomized Trial of the Addition of Ruxolitinib to BCR::ABL Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia with Molecular Evidence of Disease (SWOG Trial S1712)

Authors
K Sweet;M Othus;S Tantravahi;J Radich;J Thompson;J Mendler;C Boddy;P Kumar;E Atallah;U Perepu;J Pinilla-Ibarz;A Moseley;H Erba
Journal / Conference
ESH-iCMLf 26th Annual John Goldman CML meeting (Sept 27-29, 2024, Prague, Czech Republic), accepted, oral
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
S1712

2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg
Journal / Conference
ISHL (October 26-28, 2024 Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

Authors
S Raychaudhuri;T Gooley;M Othus;X Qu;C Shaw;K Russell;R Vyas;J Appelbaum;A Halpern;R Walter;H Erba;M Fang;M Percival
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster abstract 1530. Blood (2024) 144 (Suppl 1): 1530. doi: 10.1182/blood-2024-201213
Year
2024
Research Committee(s)
Leukemia

Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in minimal residual disease (MRD)-negative first complete remission (CR): Initial report from ECOG-ACRIN EA4151

Authors
T Fenske;X Wang;B Till;K Blum;M Lunning;H Lazarus;P Fishkin;L Shields;D Scott;A LaCasce;P Johnson;A Cashen;L Popplewell;R Dean;N Shah;N Wagner-Johnston;B Hu;B Dholaria;R Little;JW Friedberg;J Leonard;B Kahl
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Lymphoma

Trial in Progress – Alliance A052101: A randomized phase 3 trial of continuous vs. intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma

Authors
A Beaven;S Geyer;J Cohen;T Phillips;T Dockter;P Pophali;G Thanarajasingam;G Mazza;A Alencar;S Dinner;E Hsi;M Welliver;D Nikcevich;B Kahl;JW Friedberg;N Bartlett;J Leonard
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A052101

Outcome and Treatment Toxicity at Community versus Academic Sites for Patients with Rare Cancers on Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
J Jawara;L Cavalcante;S Patel;Y Chae;M Othus;R Kurzrock
Journal / Conference
ABRCMS 2024 Graduate Symposium (Nov. 13-16 in Pittsburgh, PA), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Authors
J Brown;C Ma;Q Shi;F Couture;P Kuebler;P Kumar;B Tan;S Krishnamurthi;V Chang;R Goldberg;E O'Reilly;A Shields;J Meyerhardt
Journal / Conference
Journal of the National Cancer Institute
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID39180477
PMC
PMC11630502
Study Number(s)
CTSU/C80702